From INSERM U141 and IFR Circulation-Lariboisière, Hôpital
Lariboisière, Paris, France.
Septic shock involves an acute hemodynamic failure
characterized by systemic vasodilation that is induced by bacterial
products including LPS from Gram-negative bacteria. Host immune
factors, namely proinflammatory cytokines such as TNF, mediate
LPS actions, and their main target seems to be the
cardiovascular system.6 7
The survival response of SHR to endotoxic shock and its determinants is
not known, although this acute inflammatory challenge interestingly
targets both vascular and immune systems. We therefore examined the in
vivo inflammatory responses induced by LPS in both SHR and normotensive
WKY. Furthermore, we explored the effects of LPS in whole blood to
evaluate the responses to LPS of the immune system in the 2 strains. We
show here that SHR are greatly resistant to endotoxic shock and
that this is associated with a lower production of the
proinflammatory cytokines TNF and IL-6.
Ten 12-week-old SHR were given a hypotensive drug, hydralazine,
in their drinking water over an 8-day period before LPS injection. Ten
8-week-old WKY were made hypertensive by placing a constricting clip
with an internal diameter of 0.2 mm on the right renal artery
(2K-1C rats). After 4 weeks, these hypertensive animals were used to
study the response to LPS.
Animals were weighed, and their systolic BP was measured using
the tail-cuff method (blood pressure recorder 8005, W&W
Electronic).
Animals were cared for in accordance with the European Community
standards on the care and use of laboratory animals (No. 00577).
Mortality Studies
The effect of intravenous LPS injection was evaluated in
SHR, WKY, and Wistar rats, as well as in hydralazine-treated
SHR and 2K-1C WKY. The behavior and survival of the animals was
monitored over 24 hours. The survival rate of these rats was evaluated
at 24 hours after LPS injection.
In Vivo LPS Challenge
In a series of experiments, arterial BP was continuously
recorded during endotoxin shock until 6 hours after LPS. WKY and
SHR were always studied in parallel. The rats were anesthetized
with pentobarbital, and sterile catheters were aseptically inserted
into the left carotid artery and jugular vein for measurement of BP and
for drug administration, respectively. The arterial
catheter was connected to a Statham model P23ID pressure transducer
(Gould). After a 1-hour equilibration period following the rapid
awakening, conscious rats were injected with LPS.
Whole Blood Activation
Cytokine Assays
IL-6 Assay
Nitrite/Nitrate Assay
Blood Cell Counts
Endotoxin Assay
Materials
Statistics
Enhanced Survival to LPS Shock in SHR
Twelve-week-old male Wistar rats received LPS according to the same
protocol and were observed until 24 hours after LPS administration. The
survival rate of Wistar rats (2 of 10) was not different from that of
WKY.
Resistance of SHR Is Not Related to Hypertensive State
Resistance State of SHR Is Also Observed in 5-Week-Old
Prehypertensive Rats
Hemodynamic Profile
Effects of LPS on Blood Cells
The time-course analysis of leukocyte counts showed a
peak depletion at 1 hour after LPS injection, with no difference
between the 2 strains (Figure 3A
Platelet analysis showed a progressive depletion appearing
earlier in WKY than in SHR (Figure 4A
An increase in blood hematocrit was seen in the 2 strains after
LPS injection but was significantly greater in WKY, suggesting a
greater water extravasation in these animals (Figure 4B
Systemic Proinflammatory Cytokine and NO Release
Of particular interest are the IL-6 plasma kinetics observed in SHR
versus WKY (Figure 5B
Basal NO2/NO3 plasma levels were not significantly different in SHR and
WKY (16.4±2.8 µmol/L in SHR versus 11.8±2.3 µmol/L in
WKY). NO2/NO3 plasma levels began to rise at 3 hours after LPS
(100.5±10.7 µmol/L in SHR versus 100.8±11.2 µmol/L in
WKY) and increased up to 6 hours (859.3±132.4 µmol/L in SHR
versus 814.6 ±53.3 µmol/L in WKY), with no significant
difference between SHR and WKY (Figure 5C
LPS Clearance
Whole Blood Activation
Total NO2/NO3 production was amplified in WKY whole blood but
was not significantly different from SHR whole blood production
(Figure 6C
The relative resistance of SHR to endotoxic shock therefore
depends most likely on their genetic background, which differs from
that of WKY in a polyallelic way12 13 14 and seems
to affect the immune system in addition to the
cardiovascular system.
The early hypotension that follows LPS injection was of similar
intensity in SHR and WKY, with the mean arterial pressure
being
Many authors have reported immune dysfunctions in SHR associated
with T lymphocyte and humoral defects, which may be genetically
determined and progress in parallel with
hypertension.3 4 15 16 In the present work,
some features of the immune response to LPS were found markedly
different in SHR compared with WKY.
The time course of blood cell counts during endotoxic shock
differed dramatically between the 2 strains. The basal values of
leukocyte and neutrophil counts observed in our rats were similar to
those reported in previous studies, being 50% greater in SHR than in
WKY,17 whereas monocyte counts were not
different. WBC counts showed a similar peak of depletion in both SHR
and WKY at 1 hour after LPS administration. It is noteworthy that this
early phase was similar in the 2 strains, as were the early hypotension
and the early systemic TNF release, outlining the crucial role of
secondary events. A prompt recovery in WBC counts was found in SHR,
while WKY remained profoundly leukopenic. This differential time course
of WBC count was essentially due to neutrophil counts. In agreement
with these results, an impairment of selectin-mediated leukocyte
adhesion in SHR in both basal and inflammatory conditions has been
shown18 and has been suggested to result in
relative leukocytosis in SHR. This defect of leukocyte adhesion to the
endothelium could represent a crucial
protective factor for SHR in endotoxemia, since neutrophil influx in
various tissues is known to be a determinant of organ failure.
Neutrophilia followed early neutropenia in SHR, as previously reported
in nonlethal endotoxic shock.19
TNF plasma peaks were similar in the 2 strains, and only the
residual plasma levels at 3 hours after LPS were significantly lower in
SHR. This finding is in contrast to studies by Sirén et
al20 and Hallenbeck et
al,21 who reported an enhanced release of TNF in
both serum and cerebrospinal fluid after intravenous
injection of nonlethal doses of LPS in SHR compared with WKY. Being
aware of the biological variability described for WKY among different
commercial suppliers,13 22 23 we repeated the LPS
lethality protocol in SHR and WKY purchased from 2 other animal
centers, Charles Rivers (using congenic reproduction) and CERJ,
and reproduced our results. It is noteworthy that our animals were
pathogen-free as confirmed by histological, microbial,
and serum tests made in randomized samples from each group. In
addition, the lethality protocol was repeated at different periods of
the year, and similar results were found.
The lack of direct relationships between plasma TNF levels and
LPS-induced mortality in the present work is in agreement with
studies by Feuerstein et al19 in conscious rats
and more recently by Basu et al24 in a model of
granulocyte-macrophage colony-stimulating factor-deficient
mice. Even though TNF has been shown to be directly involved in LPS
toxicity, plasma TNF levels may not necessarily reflect the actual
tissue production and may represent only a small
fraction thereof. The possibility that SHR produce less TNF at the
organ level is in fact suggested by our in vitro results in the whole
blood model showing that diluted whole blood from SHR produced
significantly less TNF than that from WKY. The differences in
cytokine production from whole blood were not accounted
for by a difference in monocyte counts.
Plasma IL-6 levels in response to LPS were markedly lower in SHR
than in WKY in terms of both net production and plasma
kinetics. Plasma IL-6 levels in WKY continuously increased up to 6
hours after LPS injection, while plasma IL-6 levels in SHR returned to
baseline values at that time. A correlation between IL-6 and mortality
rate has been already observed in human septic shock and in murine
models of endotoxemia.25 Kelly and
Cross26 showed that the relative disappearance of
IL-6 after 10 hours in nonlethally injected mice corresponded with
their symptomatic recovery, whereas IL-6 continued to
circulate up to the time of death in lethally injected mice. The low
IL-6 systemic production in SHR was associated with a low IL-6
production by SHR whole blood activated in vitro by
increasing doses of LPS. This latter result is in agreement with the
findings of Nakamura et al,27 who reported lower
IL-6 expression in renal tissue of SHR compared with WKY or Wistar
rats.
Elevation of plasma NO2/NO3 occurs especially in the rodent model
after LPS exposure and results from the high activity of the inducible
NO synthase (iNOS) isoform in rats as well as in mice. In vivo plasma
NO2/NO3 levels after LPS injection were not significantly different
between SHR and WKY either before or after LPS injection. Furthermore,
NO production from whole blood was not different between SHR
and WKY. Some authors found different abilities to produce NO in vitro
in response to inflammatory stimuli between SHR and WKY, which vary,
however, according to the cellular system studied. Splenic
macrophages from SHR produce exaggerated NO in response to Con
A,28 whereas vascular smooth muscle cells from
SHR release less NO in response to IL-1ß.29 It
is noteworthy that the locus for iNOS does not cosegregate with BP in
SHR, in contrast to Dahl sodium-sensitive hypertensive
rats.30 Thus, the expression of the iNOS pathway
does not seem to be the determinant of mortality in this endotoxic
model, in agreement with previous mouse studies, especially those in
iNOS knockout mice.31
We assayed in vivo LPS plasma kinetics in both SHR and WKY and
found no difference between the 2 strains. This result indicates that
differences in in vivo LPS clearance are unlikely to account for the
differential responses of the two strains. In fact, the observation of
a differential LPS-activated state of whole blood from the 2
strains indicates that either a cellular and/or a soluble circulating
factor is involved. Indeed, different anti-inflammatory pathways may be
involved in the relative resistance of SHR to LPS shock compared with
WKY; these pathways are under current investigation, in particular, the
anti-inflammatory cytokine and hormonal pathways. Genetic
variations in the stress response have profound effects on the immune
system and may be implicated in LPS response
variability.32 Stress hormones have been shown to
drive a shift in the Th1/Th2 balance toward
Th2,33 34 and this neuroendocrine regulation of
the immune profile may operate in the SHR strain, as already suggested
by some authors.35 36 In support of this
hypothesis, it has been shown in studies on mucosal immune responses
that SHR may preferentially develop a Th2 profile as opposed to WKY,
which may favor a Th1 profile.37 38 39 In addition,
numerous studies have reported that cellular immunity, including
delayed hypersensitivity, is depressed in
SHR.4 16 Interestingly, a Th2 environment has
been shown to protect mice from endotoxic
shock.40
In conclusion, LPS-induced inflammatory response is genetically
determined in rat strains, with SHR being relatively resistant
to endotoxic shock compared with WKY. In this context, the proper
immunoinflammatory response of SHR seems to be determinant, whereas the
hypertensive state per se is not. Because immune factors are linked to
hypertension in humans, the inflammatory response to LPS needs to be
explored in hypertensive patients compared with normotensive ones.
Received August 18, 1997;
first decision September 23, 1997;
accepted January 30, 1998.
2.
Folkow B. Physiological aspects of
primary hypertension. Physiol Rev. 1982;62:347504.
3.
Dzielak DJ. AIDS, lupus, rheumatoid
arthritishypertension? Hypertension. 1990;15:9596.
4.
Dzielak DJ. The immune system and hypertension.
Hypertension. 1992;19:I-36I-44.
5.
Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent
M, Bariéty J, Michel JB. Co-localization of myocardial fibrosis
and inflammatory cells. Lab Invest. 1994;70:286294.[Medline]
[Order article via Infotrieve]
6.
Zimmerman JJ, Ringer TV. Inflammatory host responses
in sepsis. Crit Care Clin. 1992;8:163189.[Medline]
[Order article via Infotrieve]
7.
Parrillo JE. Pathogenetic mechanisms of septic shock.
N Engl J Med. 1993;328:14711477.
8.
Desch CE, Kovach N, Present W, Broyles C, Harlan
JM. Production of human tumor necrosis factor from whole blood
ex vivo. Lymphokine Res. 1989;8:141144.[Medline]
[Order article via Infotrieve]
9.
Meager A, Leung H, Wolley J. Assays for tumor necrosis
factor and related cytokines. J Immunol
Methods. 1989;116:18.[Medline]
[Order article via Infotrieve]
10.
Aarden LA, De Groot ER, Schaap OL, Lansdorp PM.
Production of hybridoma growth by human monocytes. Eur
J Immunol. 1987;17:14111416.[Medline]
[Order article via Infotrieve]
11.
Green LC, Wagner DA, Glogowski J, Skipper PL, Wisnok
JS, Tannenbaum SR. Analysis of nitrate, nitrite, and
(15N) in biological fluids. Anal
Biochem. 1982;126:131138.[Medline]
[Order article via Infotrieve]
12.
Lindpaintner K, Kreutz R, Ganten D. Genetic variation
in hypertensive and `control' strains. Hypertension. 1992;19:428430.
13.
Johnson ML, Ely DL, Turner ME. Genetic divergence
between the Wistar-Kyoto rat and the spontaneously hypertensive rat.
Hypertension. 1992;19:425427.
14.
Bottger A, Lith H, Kren V, Krenova D, Bila V,
Vorlicek J, Zidek V, Musilova A, Zdobinska M, Wang JM, Zutphen BFM,
Kurtz TW, Pravenec M. Quantitative trait loci influencing
cholesterol and phospholipid phenotypes map to
chromosomes that contain genes regulating blood pressure in the
spontaneously hypertensive rat. J Clin Invest. 1996;98:856862.[Medline]
[Order article via Infotrieve]
15.
Khraibi AA. Association between disturbances in
the immune system and hypertension. Am J Hypertens. 1991;4:635641.[Medline]
[Order article via Infotrieve]
16.
Fu ML. Do immune system changes have a role in
hypertension? J Hypertens. 1995;13:12591265.[Medline]
[Order article via Infotrieve]
17.
Schmidt-Schönbein GW, Seiffge D, DeLano FA, Shen
K, Zweichach BW. Leukocyte counts and activation in spontaneously
hypertensive and normotensive rats. Hypertension. 1991;17:323330.
18.
Suzuki H, Schmidt-Schönbein GW, Suematsu M,
DeLano FA, Forrest MJ, Miyasaka M, Zweifach BW. Impaired
leukocyte-endothelial cell interaction in spontaneously
hypertensive rats. Hypertension. 1994;24:719727.
19.
Feuerstein G, Hallenbeck JM, Vanatta B, Rabinovici R,
Perera PY, Vogel SN. Effects of gram-negative endotoxin on levels of
serum corticosterone, TNF
20.
Sirén AL, Heldman E, Doron D, Lysko PG, Yue TL,
Liu Y, Feuerstein G, Hallenbeck JM. Release of proinflammatory and
prothrombotic mediators in the brain and peripheral
circulation in spontaneously hypertensive and normotensive Wistar-Kyoto
rats. Stroke. 1992;23:16431651.
21.
Hallenbeck JM, Dutka AJ, Vogel SN, Heldman E, Doron DA,
Feuerstein G. Lipopolysaccharide-induced production of
tumor necrosis factor activity in rats with and without risk factors
for stroke. Brain Res. 1991;541:115120.[Medline]
[Order article via Infotrieve]
22.
Kurtz TW, Morris RC Jr. Biological variability in
Wistar-Kyoto rats: implications for research with the spontaneous
hypertensive rat. Hypertension. 1987;10:127131.
23.
Rapp JP. Use and misuse of control strains for
genetically hypertensive rats. Hypertension. 1987;10:710.
24.
Basu S, Dunn AR, Marino MW, Savoia H, Hodgson G,
Lieschke GJ, Cebon J. Increased tolerance to endotoxin by
granulocyte-macrophage-colony-stimulating factor-deficient
mice. J Immunol. 1997;159:14121417.[Abstract]
25.
Yoshimoto T, Nakanishi K, Hirose S, Hiroishi K, Okamura
H, Takemoto Y, Kanamaru A, Hada T, Tamura T, Kakishita E, Higashino K.
High serum IL-6 level reflects susceptible status of the host to
endotoxin and IL-1/tumor necrosis factor. J Immunol. 1992;148:35933603.
26.
Kelly NM, Cross AS. Interleukin-6 is a better marker of
lethality than tumor necrosis factor in endotoxin treated mice.
FEMS Microbiol Immunol. 1992;89:317322.
27.
Nakamura A, Kohsaka T, Johns EJ. Differential
regulation of interleukin-6 production in the kidney by the
renal sympathetic nerves in normal and spontaneously hypertensive rats.
J Hypertens. 1993;11:491497.[Medline]
[Order article via Infotrieve]
28.
Pascual DW, Pascual VH, Bost KL, McGhee JR, Oparil S.
Nitric oxide mediates immune dysfunction in the spontaneously
hypertensive rat. Hypertension. 1993;21:185194.
29.
Singh A, Svetenk P, Larivière R, Thibault
G, Schiffrin EL. Inducible nitric oxide synthase in vascular smooth
muscle cells from prehypertensive spontaneously hypertensive rats.
Am J Hypertens. 1996;9:867877.[Medline]
[Order article via Infotrieve]
30.
Deng AY, Rapp JP. Locus for the inducible, but not a
constitutive, nitric oxide synthase cosegregates with blood pressure in
the Dahl salt-sensitive rat. J Clin Invest. 1995;95:21702177.
31.
Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice
lacking inducible nitric oxide synthase are not resistant to
lipopolysaccharide-induced death. Proc Natl Acad Sci
U S A. 1995;92:1068810692.
32.
Mason D. Genetic variation in the stress response:
susceptibility to experimental allergic encephalomyelitis and
implications for human inflammatory disease. Immunol Today. 1991;12:5760.[Medline]
[Order article via Infotrieve]
33.
Rook GAW, Hernandez-Pando R, Lightman SL. Hormones,
peripherally activated prohormones and regulation
of the Th1/Th2 balance. Immunol Today. 1994;15:301303.[Medline]
[Order article via Infotrieve]
34.
Van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry
SF. Epinephrine inhibits tumor necrosis factor-
35.
Pascual DW, Kiyono H, McGhee JR. The enteric nervous
and immune systems: interactions for mucosal immunity and inflammation.
Immunomethods. 1994;5:5672.[Medline]
[Order article via Infotrieve]
36.
Nakamura A, Kohsaka T, Johns EJ. Neuroregulation
of interleukin-6 gene expression in the spontaneously hypertensive rat
kidney. J Hypertens. 1996;14:839845.[Medline]
[Order article via Infotrieve]
37.
Chen CM, Schachter D. Elevation of plasma
immunoglobulin A in the spontaneous hypertensive rat.
Hypertension. 1993;21:731738.
38.
Plissonnier D, Levy BI, Salzmann JL, Nochy D,
Watelet J, Michel JB. Allograft-induced arterial wall
injury and response in normotensive and spontaneously hypertensive
rats. Arterioscler Thromb. 1991;11:16901699.
39.
Coste M, Wakefield T, McGhee JR, Kiyono H, Pascual DW.
Hypertensive rats manifest high IgA levels and elevated responses to
oral cholera toxin. FASEB J. 1994;8(pt 1):A515. Abstract.
40.
Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE.
Cells of Th2 cytokine phenotype prevent LPS-induced
lethality during murine graft-versus-host reaction. J
Immunol. 1994;152:10041013.[Abstract]
© 1998 American Heart Association, Inc.
Scientific Contributions
Resistance to Endotoxin Shock in Spontaneously Hypertensive Rats
![]()
Abstract
Top
Abstract
Introduction
Methods
Results
Discussion
References
AbstractSeptic shock involves
systemic vasodilation mediated by proinflammatory cytokines. In
essential hypertension, vascular and immune dysfunctions are closely
associated. The response of hypertensive animals compared with
normotensive controls to endotoxin (lipopolysaccharide; LPS)
challenge is not known. Age-matched (12 weeks) normotensive
Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) were
exposed to intravenous injection of 10 mg/kg LPS. Survival
rate at 24 hours was markedly higher in SHR than in WKY (12 of 15 and 3
of 15, respectively; P<0.01). Survival of LPS-injected
SHR was not related to their hypertension because
hydralazine-treated SHR with normalized pressure had similar
survival rates, and WKY made hypertensive by clipping of one renal
artery showed fatality similar to that of normotensive WKY. Continuous
arterial pressure and sequential plasma levels of
interleukin-6 (IL-6) and tumor necrosis factor (TNF) were measured in
LPS-treated SHR and WKY. Both the duration of the delayed hypotensive
phase and the systemic release of IL-6 were much lower in SHR than WKY,
whereas both acute hypotension and plasma TNF peak were equivalent. We
further explored in vitro the inflammatory response and showed that
LPS-activated whole blood from SHR produced less TNF and IL-6
than WKY LPS-activated whole blood. Our results indicate that SHR have
a greater ability to resist endotoxic shock than WKY. This is not
related to their hypertension but is associated with an attenuated
inflammatory response to LPS.
Key Words: rats hypertension, essential endotoxins shock cytokines nitric oxide
![]()
Introduction
Top
Abstract
Introduction
Methods
Results
Discussion
References
In essential
hypertension, in animals as well as in humans, chronic vascular and
immune dysfunctions are closely associated. The SHR is an animal model
of hypertension that has been genetically selected from the Wistar
strain and is now widely studied. Hypertension in SHR is established
progressively during aging, and numerous vascular alterations have been
reported including sympathetic hypertonia, endothelial
dysfunction, arterial compliance decrease, medial
hypertrophy, and microvascular
rarefaction.1 2 On the other hand, SHR exhibit
immune abnormalities with depressed T lymphocyte functions, decreased
delayed-type hypersensitivity, and defective
leukocyteendothelial cell
interactions.3 4 Moreover, a chronic inflammatory
process with the presence of lymphocytes and macrophages
develops early in the cardiovascular system of
SHR.5 All these observations suggest that the
cardiovascular and immune systems directly interact in
SHR.
![]()
Methods
Top
Abstract
Introduction
Methods
Results
Discussion
References
Animals
Twelve-week-old male SHR and age-matched male normotensive WKY
were used in these studies. These animals were purchased from
IFFA-CREDO (Lyon, France) as specific pathogen-free animals and housed
under a 12-hour light/dark cycle for 3 to 5 days after delivery, with
food and water given ad libitum. Twelve-week-old male Wistar rats were
also used in this study.
Escherichia coli endotoxin 026:B6 (Difco
Laboratories, Detroit, Mich) was dissolved in sterile, pyrogen-free
saline and sonicated before use. The same lot was used for all
experiments. LPS (10 mg/kg) was rapidly injected within 1 minute into
the dorsal penile vein in animals under light ether
anesthesia.
Levels of plasma TNF, IL-6, and NO2/NO3 as well as blood cell
counts were determined up to 6 hours after LPS administration. This
period of time was chosen to avoid selective bias from observation of
only rats that would survive after 6 hours. Indeed, the earliest death
was seen in the group of WKY at 6 hours after LPS injection. Different
groups of rats were killed at different time points (1, 3, and 6 hours)
after penile intravenous LPS administration, and their
plasmas were harvested and frozen at -70°C for cytokine
assays.
Blood was collected from naive, ether-anesthetized
12-week-old SHR and WKY by vena cava puncture. Whole blood activation
was studied using the method previously described for human
blood.8 Briefly, heparinized (30 UI/mL) whole
blood was diluted 10-fold in Dulbecco's modified Eagle's medium
(DMEM) before incubation and exposed for 24 hours to increasing doses
of LPS (from E. coli of the same serotype O26:B6 and lot as
used in in vivo studies). The supernatant was then harvested by
centrifugation and frozen at -70°C for
cytokine assays. In parallel, blood cell counts were performed
on each blood sample.
TNF Assay
TNF activity was measured by a specific in vitro cell
cytotoxicity assay using actinomycin-Dtreated murine fibroblast L-M
cells (American Type Culture Collection, Rockville,
Md).9 L-M cells were plated onto 96-well
microtiter plates at 7x104 cells (150 µL) per
well and incubated for 24 hours at 37°C in 5%
CO2. Medium (50 µL) containing 10 µg/mL
actinomycin-D was then added to all wells, and the cells were incubated
for 2 hours. Recombinant human TNF-
(specific activity,
3x106 U/mg) was diluted into medium standards.
Standard or sample (200 µL) were pipetted in duplicate into the first
column of wells and then serially diluted across the plate, and cells
were incubated for 24 hours. Cytotoxicity was detected by a tetrazolium
dye technique. The plates were read at 570 nm on a microtiter plate
reader (model 650, Dynatech Laboratories) against n-propyl alcohol
blanks. A standard curve relating cell cytotoxicity to doses of
recombinant human TNF-
was used to quantify TNF activity in the
samples. The sensitivity of this bioassay had a range of 0.1 to 0.2
U/mL (300 to 600 pg/mL), and the coefficient of variation was
<15%.
IL-6 activity was measured by a specific cell proliferation
bioassay using an IL-6dependent B9 hybridoma cell
line.10 The B9 cells were cultured in RPMI medium
supplemented with human recombinant IL-6 (8 U/mL), 20 µmol/L
2-mercaptoethanol, 10% heat-inactivated fetal calf serum,
100 U/mL penicillin, and 100 µg/mL streptomycin. Cells were washed
once in the above medium without added IL-6 before use for the IL-6
assay. Recombinant human IL-6 (specific activity,
107 U/mg) was diluted into medium standards.
Supernatants or plasma samples were diluted 1:100 with RPMI medium.
Fresh medium (100 µL) was added to all wells, with the exception of
the first column. IL-6 standard or diluted sample (200 µL) was
pipetted into the first column of wells and then serially diluted
across the plate. Cells were incubated for 72 hours. Cell proliferation
was detected by a tetrazolium dye technique, as described above. A
standard curve relating cell proliferation to doses of recombinant
human IL-6 was used to quantify IL-6 activity in the samples. The
sensitivity of this bioassay had a range of 0.1 to 0.2 U/mL (100 to 200
pg/mL), and the coefficient of variation was <15%.
Total NO2/NO3 concentrations in plasma and whole blood samples,
an index of NO production, were measured using the Griess
reagent.11 Nitrate was first reduced into nitrite
by treating samples (100 µL of 1/8 diluted plasma sample) with
nitrate reductase from Aspergillus (0.1 U) and 100
µmol/L NADPH for 45 minutes. NADPH, which can interfere with the
Griess reaction, was then oxidized with methosulfate phenazine (1
mmol/L) and potassium ferrocyanide (1 mmol/L). After 30 minutes,
100 µL of Griess reagent was added, and the absorbance was read at
543 nm. Concentrations were determined from a linear standard curve at
between 2 and 100 µmol/L sodium nitrite. The lower threshold of
nitrite detection in this assay is
1 µmol/L.
Venous blood samples were processed for WBC, platelets, and
hematocrit by routine methods (System 9000, automatic cell counter,
Baker Instruments).
A quantitative chromogenic limulus amoebocyte lysate
assay (Biowhittaker, Bioproducts) was used according to the
recommendations provided by the supplier.
LPS from E. coli 026:B6 serotype was from Difco, DMEM
and Krebs-Ringer solution were from Gibco (Life Technologies SARL), and
phenylephrine was from Sigma Chemical Co.
Results are expressed as mean±SEM. The experimental designs
allowed us to use a two-way repeated measures ANOVA to provide evidence
of differences related to group (WKY versus SHR) and time. The
2 test was used to compare LPS-induced
lethality in the different groups.
![]()
Results
Top
Abstract
Introduction
Methods
Results
Discussion
References
Body Weight and Systolic BP
Body weights and systolic BP at the time of experiments in
SHR, WKY, hydralazine-treated SHR, and 2K-1C WKY are given in
Table 1
. Body weights in SHR, WKY, and
hydralazine-treated SHR were not significantly different but
were lower in 2K-1C WKY (P<0.05). Systolic BP was
significantly increased in SHR and 2K-1C WKY compared with WKY
(P<0.01) and was almost normalized in
hydralazine-treated SHR.
View this table:
[in a new window]
Table 1. Weight and Systolic BP in SHR,
Hydralazine-Treated SHR, WKY, and 2K-1C Hypertensive WKY
Groups of 15 rats from each strain were given 10 mg/kg of LPS from
E. coli by direct intravenous injection in the
penile vein, and survival was recorded at 24 hours after LPS. The
animals of each strain showed signs of sepsis such as apathy,
piloerection, diarrhea, polypnea, and conjunctivitis, which were
particularly prominent in WKY. SHR did not suffer from focalized
neurological defects. Figure 1
shows the
survival curves for groups of WKY and SHR after LPS injection. Of the
SHR, 80% (12 of 15) were alive at 24 hours compared with only 20% of
WKY (3 of 15) (
2=10.8, P<0.001).
The first deaths were observed at about 6 hours after LPS in WKY, and
50% of the WKY were dead at about 9 hours after LPS, indicating that
the mechanisms leading to death operated soon after LPS administration
in this endotoxic shock model.

View larger version (14K):
[in a new window]
Figure 1. Survival rates of SHR and WKY after
intravenous injection of LPS (10 mg/kg). Survival for
groups of 15 rats is expressed by Kaplan-Meier survival curves.
**P<0.01.
In an attempt to evaluate the role of hypertension in the LPS
resistance of SHR, we studied the survival rate to LPS shock in SHR
treated with hydralazine to normalize the arterial
BP and in WKY made hypertensive by clipping of one renal artery.
Treatment of SHR with the antihypertensive drug did not modify the
resistance state of these rats to LPS (survival rate, 6 of
10;
2=1.2, P>0.05).
Similarly, the sensitivity of hypertensive 2K-1C WKY to LPS shock was
not significantly different from that of WKY (survival rate, 0 of 10;
2=2.27, P>0.05).
Young male rats from the 2 strains were also studied at 5 weeks of
age. Their systolic BP was 115±9 mm Hg in WKY and
128±10 mm Hg in SHR. Their survival rate after LPS
administration was not significantly different compared with that of
12-week-old rats of their respective strains, with survival
rates being 10 of 10 in 5-week-old SHR
(
2=1.62, P>0.05) and 3
of 10 in 5-week-old WKY (
2=2.27,
P>0.05). This result indicates that the sensitivity to LPS
shock depends on rat strain and is unrelated to the
arterial pressure.
As shown in Figure 2
, two
hypotensive phases were observed. The first hypotensive phase occurred
very rapidly after LPS intravenous injection, with a nadir
obtained at 1 hour and the arterial pressure decreasing
markedly to about 45% of the initial mean pressure levels. No
difference was observed between SHR and WKY. This period was followed
by a partial recovery until 3 hours after LPS. At that time, a
secondary hypotensive phase was observed in WKY, while SHR tended to
recover. The mean arterial pressures (expressed as a
percentage of the initial values) were found to be significantly higher
in SHR than in WKY at 4 hours and 6 hours after LPS
(P<0.05).

View larger version (18K):
[in a new window]
Figure 2. Time course of mean arterial pressure
expressed as a percentage of the value before the injection of LPS (T0)
in SHR and WKY injected with LPS. n indicates number of animals.
*P<0.05.
Basal blood cell counts were measured by using a hemocytometer in
heparinized blood samples obtained from WKY and SHR (Table 2
). The total leukocyte counts as well as
the number of lymphocytes and platelets were found to be
significantly higher in SHR than in WKY, whereas the numbers of
neutrophils and monocytes were not different.
View this table:
[in a new window]
Table 2. Blood Cell Counts in WKY and SHR
).
However, a progressive recovery up to 6 hours was observed only in SHR
(Figure 3A
). This was mainly due to the change in neutrophil counts,
which showed a rapid recovery at 3 hours followed by significant
neutrophilia at 6 hours in SHR while WKY remained profoundly
neutropenic (Figure 3B
). Mononuclear cell counts, while being greater
in SHR than in WKY at the basal time, were depressed early at 1 hour
after LPS and remained unchanged thereafter, but they were still
significantly different between SHR and WKY at 1 and 3 hours after LPS
(Figure 3C
).

View larger version (15K):
[in a new window]
Figure 3. Time course of leukocyte (A), neutrophil (B), and
mononuclear cell (C) counts after LPS injection in SHR and WKY. n
indicates number of animals. **P<0.01,
***P<0.001.
).
However, basal platelet counts were higher in SHR than WKY
(P<0.001) and remained so throughout the experiment.

View larger version (15K):
[in a new window]
Figure 4. Time course of platelet count (A) and
hematocrit (B) after LPS injection in SHR and WKY. n indicates number
of animals. *P<0.05, **P<0.01,
***P<0.001.
).
TNF and IL-6 plasma levels were assayed in 10 rats from each
strain injected in parallel with LPS and killed at different time
points: 1, 3, and 6 hours after LPS. As shown in Figure 5A
, plasma TNF peaks occurred at 1 hour
and were not different between SHR (5046±1006 U/mL) and WKY
(5469±1038 U/mL). Additional animals were killed at 30 and 90 minutes
after LPS injection to ensure that the peak in TNF was indeed achieved
by 1 hour. TNF plasma levels at 30 and 90 minutes were lower than those
at 1 hour, but they were not significantly different between SHR and
WKY. It is noteworthy that biological TNF activity persisted until 3
hours in WKY (185.4±37.2 U/mL), being significantly greater than that
in SHR (36.9±9.9 U/mL, P<0.05).

View larger version (14K):
[in a new window]
Figure 5. Time course of TNF (A), IL-6 (B), and NO2/NO3 (C)
plasma release after LPS injection in SHR and WKY. n indicates number
of animals. *P<0.05, ***P<0.001.
). Basal values were not different between the 2
strains (814±131 U/mL in SHR and 863±143 U/mL in WKY). However, in
SHR rats, IL-6 peaked at 3 hours after LPS
(196.6±24.3x103 U/mL) and decreased at 6 hours
(70.3±24.4x103 U/mL), whereas in WKY, IL-6 plasma levels
were much higher at 3 hours (557.1±46.3x103 U/mL,
P<0.001) and continued to increase at 6 hours
(797.1±142.1x103 U/mL, P<0.001).
).
LPS plasma levels, assayed at 1, 3, and 6 hours after LPS
injection, decreased progressively with time in SHR and WKY,
respectively: 0.66±0.19 versus 0.66±0.07 IU/mL at 1 hour; 0.45±0.09
versus 0.53±0.10 IU/mL at 3 hours; and 0.11±0.03 versus 0.19±0.07
IU/mL at 6 hours. The LPS plasma clearance was not significantly
different in SHR and WKY.
Heparinized 10-fold diluted whole blood from SHR and WKY was
exposed for 24 hours to increasing doses of LPS, and TNF and IL-6
biological activities were then assayed in the supernatants. Whole
blood from SHR produced significantly less TNF and IL-6 than that from
WKY (Figure 6A
and 6B
).

View larger version (26K):
[in a new window]
Figure 6. TNF (A), IL-6 (B), and NO2/NO3 (C)
production in supernatants of 10-fold diluted whole blood from
SHR and WKY in response to increasing doses of LPS after 24 hours of
incubation. n indicates number of experiments. *P<0.05,
**P<0.01, ***P<0.001.
).
![]()
Discussion
Top
Abstract
Introduction
Methods
Results
Discussion
References
We show here for the first time that SHR are markedly
resistant to endotoxic shock compared with their normotensive
controls, WKY. The resistance of SHR to in vivo LPS challenge was not
due to their high BP. Indeed, on one hand, SHR previously rendered
normotensive by treatment with an arteriolar vasodilator
(hydralazine) remained equally resistant to endotoxic
shock as untreated SHR. On the other hand, WKY rendered hypertensive by
a unilateral clip on the renal artery were highly sensitive to
endotoxic shock. Inasmuch as hypertension in SHR is progressively
established during aging, beginning at about 6 weeks with a plateau at
10 weeks of age, we were interested in following the survival rate of
young rats from the 2 strains after LPS challenge, especially that of
prehypertensive young SHR. Interestingly, the same strain-dependent
difference in LPS sensitivity was obtained in 5-week-old rats as in
12-week-old rats.
50% of the respective basal value, which indicates that the
fatal evolution of LPS shock in rats did not depend on the early
hemodynamic response to LPS but rather on the delayed
one. The time course of this secondary hypotensive phase was different
between the 2 strains. SHR clearly showed a partial recovery when WKY
did not.
![]()
Selected Abbreviations and Acronyms
BP
=
blood pressure
IL
=
interleukin
2K-1C
=
two-kidney, one clip
LPS
=
lipopolysaccharide
NO2/NO3
=
nitrite/nitrate
NO
=
nitric oxide
SHR
=
spontaneously hypertensive rats
TNF
=
tumor necrosis factor
WBC
=
white blood cells
WKY
=
Wistar-Kyoto rats
![]()
Acknowledgments
This work was supported by grants from CNAMTS/INSERM via 4API12.
We thank Michel Lupart from the Servier laboratory, Jean-Baptiste
Michel from INSERM U 367, and Michel Wassef from the cytopathology
laboratory of Hôpital Lariboisière for technical
assistance. We thank Stéphanie Lehoux for editorial
assistance.
![]()
Footnotes
Reprint requests to Catherine Bernard, INSERM U141, 41 Blvd de La Chapelle, 75475 Paris, Cedex 10, France.
![]()
References
Top
Abstract
Introduction
Methods
Results
Discussion
References
1.
Chobanian AV. Corcoran Lecture: adaptive and
maladaptive responses of the arterial wall to hypertension.
Hypertension. 1990;1989:15:666674.
, circulating blood cells, and the
survival of rats. Circ Shock. 1990;30:265278.[Medline]
[Order article via Infotrieve]
and
potentiates interleukin 10 production during human endotoxemia.
J Clin Invest. 1996;97:713719.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
![]() |
C. C. McGown and Z. L. S. Brookes Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide Br. J. Anaesth., February 1, 2007; 98(2): 163 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hernanz, A. M. Briones, M. J. Alonso, E. Vila, and M. Salaices Hypertension alters role of iNOS, COX-2, and oxidative stress in bradykinin relaxation impairment after LPS in rat cerebral arteries Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H225 - H234. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y.H. Chan, L.-L. Wang, K. L.H. Wu, and S. H.H. Chan Reduced Functional Expression and Molecular Synthesis of Inducible Nitric Oxide Synthase in Rostral Ventrolateral Medulla of Spontaneously Hypertensive Rats Circulation, October 2, 2001; 104(14): 1676 - 1681. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tsujikawa, J. Kiryu, K. Yamashiro, A. Nonaka, K. Nishijima, Y. Honda, and Y. Ogura Interactions Between Blood Cells and Retinal Endothelium in Endotoxic Sepsis Hypertension, August 1, 2000; 36(2): 250 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Andrew, Y. Deng, and S. Kaufman Fluid extravasation from spleen reduces blood volume in endotoxemia Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2000; 278(1): R60 - R65. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |